Blue Cross Blue Shield
Natera's Signatera Gains First Commercial Payor Coverage in California, Louisiana
Blue Shield of California and Blue Cross and Blue Shield of Louisiana are each covering Signatera for multiple cancer indications.
If the Center for Genomic Interpretation's in silico quality assessment catches on with payors, some labs are sure to push back or propose data sharing as an alternative.
Highmark Asks Labs for Additional Validation Data on Cancer NGS Tests; Will Other Insurers Follow?
Premium
The payor wants to see data beyond what is required through CLIA, and recommends labs use the Center for Genomic Interpretation to gauge how well tests detect and interpret variants.
In one example, Blue Cross Blue Shield of North Carolina cut $112 million in lab spending in 2020 through work with benefits manager Avalon Healthcare Solutions.
In Brief This Week: FIND, Sophia Genetics, Dante Labs, BioReference Laboratories, and More
News items for the in vitro diagnostics industry for the week of July 26, 2021.
Nov 13, 2018
Interpace Diagnostics Q3 Revenues Up 38 Percent
Aug 20, 2018